SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Ethereum is a global, open-source platform for decentralized applications. In other words, it is a decentralized blockchain platform that enables developers to build and deploy smart contracts and applications without central authority control. Unlike Bitcoin, which primarily functions as digital currency, Ethereum operates as a programmable global computer where developers can create any type of decentralized service.   The platform hosts over $14 billion in DeFi applications with hundreds of thousands of active users across financial protocols, NFT marketplaces, and gaming platforms. Its transition to Proof of Stake in September 2022 reduced energy consumption by over 99%, addressing environmental concerns while strengthening network security.  The network operates through thousands of independent validator nodes that process transactions and execute smart contracts on the Ethereum Virtual Machine. Smart contracts are self-executing programs written in Solidity that automatically carry out agreements when conditions are met, eliminating intermediaries like banks or brokers.   Validators stake ETH as collateral to propose and validate blocks, earning rewards for honest participation while facing penalties for malicious behavior. The EIP-1559 upgrade introduced a dynamic base fee mechanism that burns ETH with each transaction, creating deflationary pressure during high network activity when more ETH is burned than issued to validators.  Vitalik Buterin proposed Ethereum in 2013, but seven co-founders helped build it, including Gavin Wood who created Solidity and the EVM technical specification, and Joseph Lubin who founded ConsenSys. The project launched in July 2015 after raising over $18 million through crowdfunding, quickly becoming the largest blockchain developer community. Major milestones include the 2020 Beacon Chain launch, the 2021 London hard fork implementing fee burning, and the 2022 Merge to Proof of Stake.   Ether (ETH) serves multiple functions: paying transaction fees (gas), staking to secure the network and earn 3-5% annual yields, serving as collateral in DeFi protocols, and purchasing NFTs and digital assets. The asset is increasingly adopted by traditional institutions, with publicly traded companies adding ETH to corporate treasuries to generate staking yields while maintaining blockchain exposure, and in 2024, the SEC approved spot Ethereum ETFs, allowing traditional investors to gain exposure through conventional brokerage accounts.  Ethereum's roadmap focuses on dramatically increasing transaction capacity to over 100,000 per second, reducing confirmation times, and enhancing decentralization while maintaining security against future threats like quantum computing.

Ethereum

Ethereum is trending as community members closely monitor the progress of the Crypto Clarity Act, with optimism that legislative resolution will unlock significant institutional capital. Traders are actively debating technical breakout levels near the two thousand dollar mark while analyzing the impact of potential regulatory milestones and macro-economic factors on market sentiment.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

The market is reacting to geopolitical developments in the Middle East and anticipation of upcoming economic data, with participants actively debating whether recent military pauses signal a lasting de-escalation or just a tactical lull. Bullish traders are focused on potential gaps and momentum plays, while bears remain skeptical, closely monitoring bond yields and high AI capital expenditures for signs of a broader market correction.

Shiba Inu (SHIB) is a decentralized, community-led cryptocurrency ecosystem built on the Ethereum blockchain. Originally launched as a meme-based project, it has evolved into a comprehensive financial ecosystem designed to offer a decentralized alternative to traditional banking. Its main value proposition lies in its transition from a social phenomenon into a functional utility network, supported by a vast global community known as the ShibArmy and a commitment to 100% community ownership with no central leadership.  The ecosystem features its own decentralized exchange, ShibaSwap, where users can trade, provide liquidity, and earn rewards. To address Ethereum’s high costs and slow speeds, the project utilizes Shibarium, a Layer 2 scaling solution that processes transactions faster and more affordably.  The project employs a unique three-token model to manage its economy and governance. SHIB serves as the primary currency for trading and payments, while LEASH offers scarcity-based incentives for dedicated supporters. BONE acts as the governance token, allowing holders to vote on proposals through the Doggy DAO and serving as the native gas token for the Shibarium network.

Shiba Inu

Shiba Inu is seeing heightened community engagement driven by aggressive token burn activity and speculation about a potential rally. Investors remain divided, with some betting on a parabolic shift in momentum while others cite concerns over the massive circulating supply.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

The United States Oil Fund is trending due to heightened geopolitical tensions and supply fears stemming from military escalations in the Middle East, specifically affecting tanker traffic in the Strait of Hormuz and Red Sea. The community is actively debating whether current price moves are driven by a genuine supply shock or speculative trading, with many participants sharply divided on the sustainability of the rally versus the potential for a sudden diplomatic ceasefire.

iShares Silver Trust - Fractional undivided beneficial interests

iShares Silver Trust

The iShares Silver Trust (SLV) is currently experiencing high volatility driven by geopolitical tensions in the Middle East and ongoing uncertainty regarding U.S. debt and inflationary pressures. The community remains deeply divided, with long-term investors actively debating whether the metal is currently at a generational buy level or remains susceptible to further manipulation and downside risk.

Direxion Shares ETF Trust - Direxion Daily S&P Biotech Bear 3X ETF

Direxion Daily S&P Biotech Bear 3X Shares

Investors are actively debating the potential for a biotech sector pullback as the symbol faces pressure from rising yields and oil prices, while community sentiment remains split between technical chart patterns and speculative M&A activity. The ongoing volatility has created intense interest in the ETF's daily swings, with many traders closely monitoring support levels in the underlying biotech index to time their entries.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is seeing intense community engagement as investors eagerly anticipate the release of Phase 3 IZAR-1 trial data, which many view as a primary catalyst for a significant re-rating or potential M&A activity. Discussions are currently dominated by speculation over the timing of the readout, debates regarding the company's valuation compared to sector peers, and a shared sentiment that the stock remains heavily influenced by institutional positioning.

Core Scientific, Inc. engages in the business of operating a purpose-built facility for digital asset mining and provision of blockchain infrastructure, software solutions, and services. It operates under the Mining and Hosting segments. The Mining segment focuses on bitcoin mining for the company's own account. The Hosting segment includes blockchain infrastructure and third-party hosting business. The company was founded by Michael Jeffrey Levitt and Darin Feinstein on December 13, 2017 and is headquartered in Dover, DE.

Core Scientific Inc - Ordinary Shares - New

Core Scientific Inc

Core Scientific is trending as investors monitor the company's strategic pivot toward AI infrastructure and high-performance computing, with sentiment heavily influenced by recent capital-raising initiatives and the ongoing demand for data center power capacity. Community discussion is focused on the company's ability to secure new anchor tenants for its data center portfolio and the overall execution of its long-term growth roadmap.

RTX Corp. is an aerospace and defense company, which engages in the provision of aerospace and defense systems and services for commercial, military, and government customers. It operates through the following segments: Collins Aerospace Systems (Collins), Pratt and Whitney, Raytheon Intelligence and Space (RIS), and Raytheon Missiles and Defense (RMD). The Collins segment manufactures and sells aero structures, avionics, interiors, mechanical systems, mission systems, and power controls. The Pratt and Whitney segment includes the design and manufacture of aircraft engines and auxiliary power systems for commercial, military, and business aircraft. The RIS segment is involved in the development of sensors, training, and cyber and software solutions. The RMD segment offers end-to-end solutions to detect, track, and engage threats. The company was founded in 1922 and is headquartered in Arlington, VA.

RTX Corp

Raytheon Technologies Corporation

Raytheon Technologies is currently trending as investors look to capitalize on the stock's significant backlog and recent contract wins amid an intensified focus on defense infrastructure. Community members are actively debating the company's role in global weapons replenishment cycles and evaluating its position in the broader aerospace sector ahead of key financial disclosures.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle is experiencing significant volatility and downward pressure as market participants debate the company's aggressive AI capital expenditure and high debt levels amid broader sector concerns. The community remains deeply polarized, with some investors highlighting a massive government contract and long-term infrastructure backlog as bullish indicators, while others express frustration over management's silence and the stock's persistent decline.

statis crypto Watchlist

Bitcoin

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Kuehn Law Encourages Investors of TG Therapeutics, Inc. to Contact Law Firm

Kuehn Law Encourages Investors of TG Therapeutics, Inc. to Contact Law Firm Kuehn Law Encourages Investors of TG Therapeutics, Inc. to Contact Law Firm PR Newswire NEW YORK, July 21, 2026 NEW YORK, July 21, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating...

TG Therapeutics (TGTX) Gains as Its Key Drug Exceeded Expectations

TG Therapeutics (TGTX) Gains as Its Key Drug Exceeded Expectations...

TGTX Stock Rises On Wall Street Price Target Hike, New Schizophrenia Trial Launch

Equity

Bank of America analyst Alec Stranahan raised his price target on TG Therapeutics to $20 from $17 but kept an ‘Underperform’ rating on the shares.


TG Therapeutics Begins Phase II Study With Briumvi in Schizophrenia

TGTX initiates a phase II study evaluating Briumvi in adult patients with treatment-resistant schizophrenia. Shares rise.

Will Briumvi's Strength Continue to Aid TGTX's Top Line in Q2?

TG Therapeutics continues to witness rising Briumvi demand. Investors are closely watching the sales numbers of the drug.

Immunovant (IMVT) Up 3.6% Since Last Earnings Report: Can It Continue?

Immunovant (IMVT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

TG Therapeutics Stock Rises Thursday: What's Driving The Gains?

TG Therapeutics shares are trading higher on Thursday as traders keep leaning into recent upbeat clinical updates around BRIUMVI.read more...

TGTX Stock Continues Rally For 8 Straight Sessions On New BRIUMVI Clinical Data

Recent announcements from TG Therapeutics have buoyed optimism on the long-term potential of its Briumvi drug. 

TG Therapeutics (TGTX) Soars 7.5%: Is Further Upside Left in the Stock?

TG Therapeutics (TGTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

TGTX Rises on Positive Phase I Data for Subcutaneous Briumvi in MG

TG Therapeutics gains after positive phase I data for subcutaneous Briumvi in myasthenia gravis or MG, while a phase II study in MG gets underway.

TG Therapeutics is a fully integrated, commercial stage, biotechnology company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI® (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features. For more information, visit www.tgtherapeutics.com, and follow us on X (formerly Twitter) @TGTherapeutics and on LinkedIn.

TG Therapeutics Inc

Bearish Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

The S&P 500 ($SPY) is headed towards another losing week. What do you think the index's return will look like next week? Vote and explain your reasoning in the comments.

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Fiscal Period	Estimated	Reported	Surprise	Result
Q2 '26	$0.32	--	--	N/A
Q1 '26	$0.28	$0.12	-56.44%	MISSED
Q4 '25	$0.35	$0.14	-60.28%	MISSED
Q3 '25	$0.22	$2.43	1010.24%	BEAT
Q2 '25	$0.21	$0.17	-19.49%	MISSED

Feed

News

Sentiment

Earnings

Fundamentals

Info

TGTXTG Therapeutics Inc

Upcoming Earnings: Q2 '26

Historical Earnings

Latest TGTX News